Cross-industrial applications of organotypic models.

Katarzyna Kopanska

doi:10.14573/altex.2112202

Abstract

Recent advances in microphysiological systems (MPS) promise a global paradigm shift in drug development, diagnostics, disease prevention, and therapy. The expectation is that these systems will model healthy and various diseased stages and disease progression to predict toxicity, immunogenicity, ADME profiles, and treatment efficacies. MPS will provide unprecedented human-like physiological properties of in vitro models, enabling their routine application in the pharma industry and thus reducing drug development costs by lowering the attrition rate of compounds. We showcased MPS application diversity across different industries during the TEDD Annual Meeting on 14th October 2021 in Wädenswil, Switzerland. The goal was to promote cross-sectoral collaboration of academia and industry to further pave the way for developing next-generation MPS based on 3D cell culture, organoid, and organ-on-chip technology and their widespread exploitation. To enable visionary projects and radical innovations, we covered multidisciplinary fields and connected different industry sectors, like pharma, medtech, biotech, cosmetics, diagnostics, fragrances, and food, with each other.

Highlights

The scientific part of the meeting started with a keynote by Dr Olivier Frey, Vice President and Head of Technology & Platforms at InSphero
Dr Markus Rimann, head of the TEDD Competence Centre (Tissue Engineering for Drug Development and Substance Testing), pointed out that the 3Rs initiative is at the core of the network, and the network aims for future-oriented systems such as microphysiological systems (MPS) to replace animal testing, an essential goal in the socio-political context
Diagnostic tools for early detection of liver disease are lacking. She described a 3D, multicellular in vitro system composed of HepaRG cells, THP-1, and hTERTHSC that can mimic the main features of hepatic fibrosis as described in the liver fibrosis adverse outcome pathway (AOP:38)

Summary

Introduction

The scientific part of the meeting started with a keynote by Dr Olivier Frey, Vice President and Head of Technology & Platforms at InSphero. MPS will provide in vitro models with unprecedented human-like physiological properties, enabling their routine application in the pharma industry and reducing drug development costs by lowering the attrition rate of drug candidates. Dr Markus Rimann, head of the TEDD Competence Centre (Tissue Engineering for Drug Development and Substance Testing), pointed out that the 3Rs initiative is at the core of the network, and the network aims for future-oriented systems such as MPS to replace animal testing, an essential goal in the socio-political context.

Results

Conclusion